About this trial
The purpose of this study is to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer.
Patient Profile
ER+/HER2- Early Breast Cancer
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Waterford, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | NATALEE |
|---|---|
| Number: | 18-41 (CLEE011O12301C) |
| Full Title: | A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negartive Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE). |
| Principal Investigator: | Prof John Crown (St Vincent's University Hospital) |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Novartis Pharmaceuticals |
| Recruitment Started: |
Global: 2018 Ireland: 2019 |
| Global Recruitment Target: | 4,000 |
|---|---|
| Ireland Recruitment Target: | 110 |